- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Morgan Stanley initiates ADARx stock with overweight rating | 1 | Investing.com | ||
| Di | Morgan Stanley startet Beobachtung von ADARx Pharmaceuticals mit "Overweight" | 2 | Investing.com Deutsch | ||
| Di | TD Cowen initiates ADARx stock with buy rating on siRNA tech | 1 | Investing.com | ||
| Di | TD Cowen startet Beobachtung von ADARx mit "Buy" - Potenzial durch siRNA-Technologie der nächsten Generation | 1 | Investing.com Deutsch | ||
| 01.10. | ADARx erzielt nach Ausübung der Mehrzuteilungsoption Bruttoerlöse von 513,2 Mio. US-Dollar | 1 | Investing.com Deutsch | ||
| ADARX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 01.10. | ADARx raises $513.2M as underwriters exercise IPO option | 1 | Investing.com | ||
| 01.10. | ADARx Pharmaceuticals Inc.: ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering | 213 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced... ► Artikel lesen | |
| 28.09. | Can AbbVie's Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? | 20 | Insider Monkey | ||
| 28.09. | ADARx Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.09. | HBM Healthcare erhöht Beteiligung an Adarx im Rahmen des Börsengangs | 6 | cash | ||
| 28.09. | HBM Healthcare Investments Raises Stake In ADARx Pharma | 5 | RTTNews | ||
| 28.09. | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | 653 | EQS Group (DE) | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| 25.09. | ADARx Pharmaceuticals surges following upsized IPO | 2 | Seeking Alpha | ||
| 25.09. | Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut | 2 | MedCity News | ||
| 25.09. | Adarx Pharmaceuticals: 55 % des Börsengangs an nur zehn Investoren zugeteilt | 3 | Investing.com Deutsch | ||
| 25.09. | ADARx Pharmaceuticals raises $446.3 million in upsized US IPO | 1 | Reuters | ||
| 25.09. | siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range | 2 | Renaissance Capital | ||
| 25.09. | ADARx scores upsized $446M IPO, while fellow RNA biotech City Therapeutics maps out Nasdaq plans | 3 | FierceBiotech | ||
| 25.09. | RNAi drug specialist ADARx raises $446M IPO | 1 | BioPharma Dive | ||
| 25.09. | ADARx Pharmaceuticals prices upsized IPO at $17 per share | 1 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on RAP-219 trial wins | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250 million stock offering at $17.50 | ||
| KYMERA THERAPEUTICS | 112,56 | -0,06 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,640 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
Das Unternehmen ADARX PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,35 % bei einem Aktienkurs von 17,070 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADARX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.